Research & Development



  以上的過程走完,婚禮也就結束了,剩下的就是霍氏大宴賓客的場面。   平叟笑道︰“一雞死一雞鳴,解散鐵坊並非是壞事,雲氏答應給我們一套制錢流水線,大女現在要做的就是儲存大量的銅。我卓氏不再冶鐵,改鑄錢了,地點就該在富貴鎮!”2014福利彩票3d   右賢王率騎數攻漢邊郡,並入河南,襲擾朔方郡,殺擄民眾,雖然被邊軍一一擊退,然而,我大漢也損失慘重。2014福利彩票   “沒問題,他們可以煉焦,我的權勢還沒有大到不允許別人煉焦的地步。告訴那些人,直接去干就好,用不著問雲氏同意不同意,如果他們煉焦成功,記得賣給雲氏,這東西對雲氏來說永遠都不夠。”   “打開!”2014注册送彩票体验金   雲音似乎很喜歡這個伯伯,也不哭,咯咯的笑著去抓霍去病探出來的手指。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo